A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer (TNBC)
Latest Information Update: 12 Feb 2024
At a glance
- Drugs Veliparib (Primary) ; Carboplatin; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Early breast cancer; Triple negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms BrighTNess
- Sponsors AbbVie
- 27 Jan 2022 Primary endpoint (Pathological Complete Response (pCR) has not been met according to the results published in the Annals of Oncology
- 27 Jan 2022 Results published in the Annals of Oncology
- 15 Jan 2021 Status changed from active, no longer recruiting to completed.